2QFY05: Pharma sector revisited - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

2QFY05: Pharma sector revisited

Nov 8, 2004

Be it a bull run or a free fall, pharma sector is there for investors rescue in either cases. In the performance review of June quarter, we noticed that the pharma sector cushioned investors from the disgrace of free fall of the market. In this quarter too, the pharma sector has outperformed the Sensex by almost 4%! While the BSE Sensex has risen by almost 16.4% since July 2004, the pharma index is up by 20.7% in the same period.

The second quarter of the financial year was a mixed bag for pharma companies in our universe (5 MNC and 6 Indian companies). The companies under our universe grew by 11% YoY in sales. While these are just numbers, let’s delve further into the quarter under consideration.

Firstly, investors have to bear in mind that MNC pharma companies largely cater to the domestic market while Indian companies have increased the contribution to revenues from international markets.

Rs m) Sep Q'03 Sep Q'04 Change
Net Sales 39,625 43,943 10.9%
Operating Profit (EBDIT) 8,828 10,375 17.5%
Operating Profit Margin (%) 22.3% 23.6%  
Profit after Tax/(Loss) 6,716 8,557 27.4%
Net profit margin (%) 16.9% 19.5%  

MNC Companies

Looking at MNC’s performance, it can be said that the growth in the topline was pretty good considering their old product portfolio. Glaxo and Aventis Pharma led the pack. In case of Glaxo, the major driver of the topline was its merger with Burroughs Wellcome. If one excludes this merger effect, the growth in topline stands at 13%, which was basically driven by the growth of its vaccine portfolio. Aventis Pharma showed growth on the exports side, which grew by 63% in the quarter. Some of its brands in the domestic market also posted double-digit growth. The other three major companies did not show any significant growth in the quarter. With the impending patent regime, MNC companies are well poised to capitalize on the domestic opportunity. However, the gains will be realised over a period of time as opposed to 2005 itself.

MNC Companies Net Sales Operating Profit Net Profit
Sep Q'03 Sep Q'04 Change Sep Q'03 Sep Q'04 Change Sep Q'03 Sep Q'04 Change
Aventis 1628 1,841 13.1% 364 618 69.8% 261 425 62.8%
Abbott 1041 1,046 0.5% 261 230 -11.9% 196 433 120.9%
Glaxo 3114 3,736 20.0% 786 1,180 50.1% 573 1,725 201.0%
Novartis 1245 1,254 0.7% 147 245 66.7% 265 217 -18.1%
Pfizer 1349 1,342 -0.5% 156 170 9.0% 123 142 15.4%
Total 8377 9,219 10.1% 1,714 2,443 42.5% 1,418 2,942 107.5%
Operating Margin 20.5% 26.5%              
Netprofit Margin 16.9% 31.9%              

Indian Companies

In the ‘Equitymaster’ pharma universe, we have 6 Indian companies under coverage viz. Cipla, Dr Reddy’s, Nicholas Piramal, Ranbaxy, Wockhardt and Sun Pharma. The consolidated performance of these companies was encouraging (sales growth of 11% YoY).

On the international side, poor performance by Dr Reddy’s and lackluster growth in sales of Ranbaxy subdued the overall performance. Going forward, the growth in topline is likely to accelerate for companies like Ranbaxy and Dr Reddy’s. The stellar performance of Cipla continued in this quarter too (topline growth of 28%). This performance was basically led by the exports of formulations (up 76% YoY).

Indian Companies Net Sales Operating Profit Net Profit
Sep Q'03 Sep Q'04 Change Sep Q'03 Sep Q'04 Change Sep Q'03 Sep Q'04 Change
Cipla 4,512 5,814 28.9% 895 1,319 47.4% 695 959 38.0%
Dr Reddy's 5,236 5,242 0.1% 1,134 697 -38.5% 889 464 -47.8%
Nicholas Piramal 3,684 3,757 2.0% 757 824 8.9% 523 560 7.1%
Ranbaxy 12,131 13,614 12.2% 2,801 3,125 11.6% 1,871 2,004 7.1%
Wockhardt 2,852 3,175 11.3% 608 800 31.6% 491 558 13.6%
Sun Pharma 2,833 3,122 10.2% 919 1,167 27.0% 829 1,070 29.1%
Total 31,248 34,724 11.1% 7,114 7,932 11.5% 5,298 5,615 6.0%
Operating Profit Margin 22.8% 22.8%              
Net Profit Margin 17.0% 16.2%              

What to expect?

While MNC pharma companies are totally dependent on the Indian market for growth (Aventis being the exception), we expect contribution from exports to increase for Indian pharma majors, despite a challenging environment (the challenge is both on the pricing side as well as on the regulatory side). While Indian companies are looking to grow their topline by focusing in bulk drugs and generics segment, MNC companies are eyeing the opportunity post 2005, when the new patent regime will come into force in India.

In our view, the rationale to invest in Indian pharma company or a MNC is a matter of risk profile. Indian pharma majors will have an uphill task to grow in the domestic market (post the patent regime) and compete with the already established global majors in the international markets. As far as MNC companies are concerned, the access to R&D capabilities and products provide significant competitive advantage. At the same time, Indian companies have cost and scale advantage. And, the R&D activity that is being pursued by Indian pharma companies will bear its fruits in long run.


Equitymaster requests your view! Post a comment on "2QFY05: Pharma sector revisited". Click here!

  

More Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 18, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS